← Back to Search

Procedure

Transseptal Group for Neurocognitive Disorder (TRAVERSE Trial)

N/A
Waitlist Available
Led By Gregory Marcus, MD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 6 months post-ablation
Awards & highlights

TRAVERSE Trial Summary

This trial will compare two methods of left ventricular ablation to prevent cerebral emboli and neurocognitive decline in adults with ventricular tachycardia or premature ventricular contractions.

Eligible Conditions
  • Neurocognitive Disorder

TRAVERSE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 6 months post-ablation
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 6 months post-ablation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
cerebral embolic lesion incidence
overall neurocognitive function, change
Secondary outcome measures
complications related to the ablation procedure, rate
new cerebral embolic lesions, number
physical activity (MET-min/week), change
+3 more

TRAVERSE Trial Design

2Treatment groups
Active Control
Group I: Transseptal GroupActive Control1 Intervention
Transseptal Aortic Approach Catheter Ablation Procedure
Group II: Retrograde GroupActive Control1 Intervention
Retrograde Aortic Approach Catheter Ablation Procedure

Find a Location

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor
2,500 Previous Clinical Trials
15,236,318 Total Patients Enrolled
Gregory Marcus, MDPrincipal InvestigatorUniversity of California, San Francisco
3 Previous Clinical Trials
3,072 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the desired outcome of this investigation?

"The principal target of this trial, assessed between the beginning (pre-ablation) and 6 months after ablation is to evaluate cerebral embolic lesion frequency. Subsidiary purposes include a quality of life composite score change quantified with the SF-12 survey, as well as alterations in symptoms linked to VT/PVC."

Answered by AI

Is there an available capacity for participants in this research endeavor?

"As reported on the clinicaltrials.gov database, this trial is currently accepting volunteers. The study was first posted on July 2nd 2019 and has been updated as recently as September 6th 2022."

Answered by AI

What is the geographic scope of this clinical trial?

"24 clinical centres are involved in this medical experiment, including the University of Colorado at Denver, University of California San Francisco and Houston Methodist Research Institute. Additionally, there are myriad other sites providing support to this study."

Answered by AI

Approximately how many subjects have been recruited for this clinical experiment?

"Affirmative. Clinicaltrials.gov confirms that the study, initially posted on July 2nd 2019, is currently seeking participants. 150 individuals need to be recruited from 24 different trial sites."

Answered by AI

Who else is applying?

What state do they live in?
Utah
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
0
What site did they apply to?
University of Utah

Why did patients apply to this trial?

I am a struggling individual who really needs money to get buy and would put their own body on the line.
PatientReceived no prior treatments
Recent research and studies
clinicaltrials.govStudy
Transseptal vs Retrograde Aortic Ventricular Entry to Reduce Systemic Emboli
2019. "Transseptal vs Retrograde Aortic Ventricular Entry to Reduce Systemic Emboli". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03946072.
~27 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top